Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2022
Date of Report: July 28, 2022
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
Key Financial Metrics
The provided filing text does not contain specific financial data. This Form 6-K serves as a cover document referencing a press release (Exhibit 99.1) but does not include the text of that release or any financial statements within the body of the document.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The document solely indicates the submission of a press release dated July 28, 2022, without summarizing its contents.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risk factors, or descriptions of unusual items. These details are presumably contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Investor Verification Checklist
- Review the full text of the Press Release dated July 28, 2022 (Exhibit 99.1) to understand the specific corporate event or announcement triggering this filing.
- Verify if the press release contains updated clinical trial data, partnership announcements, or regulatory milestones, as these are typical drivers for Form 6-K filings by biopharmaceutical companies.
- Check subsequent filings (e.g., Form 20-F or quarterly reports) for the financial impact of the events described in the July 28, 2022 press release.